Negative / Null Result ReportOpen accessMedicine· cited by 9

Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma

Akhilesh Mishra; Ajay Sharma; Kuldeep Gupta; Dhanush S. Banka; Burles A. Johnson; Hoffman-Censits Jean; Peng Huang; David J. McConkey · 2026 · Science Advances

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Optimizing dosing strategies is critical to balance effectiveness and toxicity, especially for drugs with narrow therapeutic windows such as antibody-drug conjugates (ADCs). This study evaluates whether positron emission tomography (PET) imaging targeting Nectin-4 can noninvasively quantify the real-time interaction of the ADC enfortumab vedotin (EV) with tumors in urothelial carcinoma. Using the imaging agent [ 68 Ga]AJ647, dynamic changes in the interaction of EV with Nectin-4 were measured across preclinical models and correlated with therapeutic responses. PET imaging identified dose-depen

Abstract by Akhilesh Mishra; Ajay Sharma; Kuldeep Gupta; Dhanush S. Banka; Burles A. Johnson; Hoffman-Censits Jean; Peng Huang; David J. McConkey, Science Advances (2026) — licensed CC BY 4.0.

Read the full paper (open access)